Bicycle Therapeutics Q2 FY26 net loss narrows to $50.3 million; R&D expenses drop 42% to $41.2 million - BCYC News | RalliesBicycle Therapeutics Q2 FY26 net loss narrows to $50.3 million; R&D expenses drop 42% to $41.2 million
B
BCYC• Pipeline updates
- Initiated a Phase 2 trial of nuzefatide pevedotin in recurrent pancreatic ductal adenocarcinoma, dosing the first patient in April at 8 mg/m² Q2W.
- Management reiterated plans to start a Phase 1 trial for BT1702, an MT1-MMP-targeting Bicycle Radioconjugate, in 2027.
Q2 financial results
- Bicycle Therapeutics posted a Q2 net loss of $50.3 million, narrowing from $79.0 million a year earlier; loss per share improved to $0.72 from $1.14.
- R&D expense fell 41.97% to $41.2 million; G&A expense dropped 24.32% to $14.0 million, following a March 2026 workforce reduction.
- Revenue slid to $629,000 from $2.92 million; cash and cash equivalents declined to $510.1 million at June 30 from $628.1 million at year-end.
•
